High Demand Characterizes Launch of Legal Psilocybin Access in Oregon

September 21, 2023 11:07:01

This June, America’s first-ever service center for psilocybin-assisted therapy opened in Oregon, marking both the state and country’s first definitive steps toward legalizing therapeutic psilocybin for the masses. Oregon is the first state in the country to offer psilocybin-related treatments; the state went a step further in June by opening the first center where eligible adults could experience guided psilocybin trips.

Epic Healing Eugene will give Oregonians aged 21 years and older the opportunity to experience guided psychedelic trips for around six hours without the need for referrals or prescriptions. The center currently has more than 3,000 people on its waitlist and will likely attract more customers as time passes.

Psilocybin is the main hallucinogenic element in magic mushrooms and it has exhibited significant potential as a treatment for mental disorders such as depression, anxiety and post-traumatic stress disorder (PTSD) in a growing number of studies. A recent surge in psychedelic research found that psilocybin and a variety of other psychedelics have potent mental-health benefits and could function as alternative mental-health treatments, leading to an explosion in interest among the mainstream public and pharmaceutical firms.

Lawmakers across the country are now considering the possibility of legalizing therapeutic psychedelic use based on studies painting hallucinogens as potentially safer and more effective alternatives to conventional mental-health treatments.

Psychedelic reform proponents hope the efforts to legalize hallucinogens in Oregon could trigger a mental health care revolution. Experts estimate that close to 50% of Americans suffering from mental disorders do not obtain the treatment they need, even though 47% of U.S. adults report experiencing anxiety while 39% report depression symptoms.

Those who do seek treatment for their mental ailments often have to deal with short- and long-term side effects such as sexual dysfunction, diabetes, headaches, serotonin syndrome, gastrointestinal bleeding, mania or hypomania, blood disorders, liver disorders, metabolic syndrome and seizures. Psychedelics have proven in numerous studies that they can alleviate numerous mental-health symptoms over the long-term with fewer side effects and at lower doses.

With states such as Oregon and Colorado taking to psychedelics in a major way, a wave of psychedelic reform may just sweep over the United States, resulting in the launch of dozens of state-legal psychedelic sectors. Voters in Colorado approved a measure to legalize the use of psilocybin, and the California Legislature recently advanced a bill that would legalize the possession and consumption of certain psychedelic plants.

The Oregon Psilocybin Services Section, which regulates Oregon’s fledgling psychedelic industry, says it has received hundreds of thousands of inquiries from across the globe about the specifics and potential benefits of a regulated therapeutic psychedelic industry.

The positive response that the Oregon psilocybin program is garnering is an encouragement to psychedelic drug-development companies such as atai Life Sciences N.V. (NASDAQ: ATAI), which seek to address the demand for new treatments for mental-health disorders.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN